AbbVie suing EMA

AbbVie Inc. (NYSE:ABBV) said it filed two suits against EMA in January in the European Union General Court "seeking to protect AbbVie's confidential and commercially-sensitive information" for autoimmune drug Humira adalimumab. The company is seeking to prevent EMA from releasing raw, patient-level data from clinical trials of Humira in response to two requests that were submitted to the agency last year. One of the requests was rumored to come from UCB Group (Euronext:UCB), which markets competing autoimmune drug Cimzia certolizumab pegol. UCB could not be reached for comment. AbbVie declined to provide the court documents, which have not yet been made public.

AbbVie said in a statement that it "supports transparency of clinical research and safety information" but does not support the disclosure of commercially confidential information "that does not meaningfully contribute to the scientific review or evaluation of [its] products." ...